Joseph Ament, MD
Hematology & Oncology · New York, NYNPI 1740212166
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 365 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations.
Across 365 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$1K
- GSK$720
- Novo Nordisk$454
- Pfizer$434
- Johnson & Johnson$313
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,340100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 69 | $1,349 |
| AbbVie | 81 | $1,255 |
| GSK | 44 | $720 |
| Novo Nordisk | 23 | $454 |
| Pfizer | 30 | $434 |
| Johnson & Johnson | 16 | $313 |
| Kowa Pharmaceuticals America, Inc. | 19 | $286 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $245 |
| Exact Sciences | 9 | $187 |
| Bausch Health US, LLC | 8 | $164 |
| Lilly USA, LLC | 7 | $148 |
| Stemline Therapeutics Inc. | 5 | $99 |
| Gilead | 6 | $87 |
| Merck | 4 | $69 |
| IBSA Pharma Inc. | 2 | $69 |
| Seagen Inc. | 4 | $62 |
| Novartis | 4 | $56 |
| Phathom Pharmaceuticals, Inc. | 2 | $43 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Genentech USA, Inc. | 2 | $33 |
| Bayer | 2 | $32 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $22 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| Verastem, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $17 |
| Puma Biotechnology, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Bristol Myers Squibb | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,340 in reported general payments places this provider in the 65th percentile of 967 hematology & oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 97 | $107,880 |
| JanuviaSitagliptin Phosphate | 69 | $72,728 |
| EliquisApixaban | 78 | $48,962 |
| OrgovyxRelugolix | 13 | $35,146 |
| MounjaroTirzepatide | 16 | $16,290 |
| FarxigaDapagliflozin Propanediol | 11 | $13,488 |
| LinzessLinaclotide | 15 | $12,818 |
| SynthroidLevothyroxine Sodium | 115 | $11,089 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $7,986 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,040 |
| Spiriva RespimatTiotropium Bromide | 12 | $6,136 |
| Amlodipine Besylate | 533 | $4,199 |
| Pitavastatin Calcium | 20 | $3,907 |
| Metoprolol Succinate | 155 | $3,587 |
| LumiganBimatoprost | 13 | $3,294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $454 | $107,88097 claims |
| MerckJanuvia | $69 | $72,72869 claims |
| PfizerEliquis | $434 | $48,96278 claims |
| AbbVieLinzess, Synthroid, Lumigan | $1,255 | $27,202143 claims |
| AstraZenecaFarxiga, Symbicort | $1,349 | $21,47438 claims |
| Lilly USA, LLCMounjaro | $148 | $16,29016 claims |
| GSKBreo Ellipta | $720 | $7,04017 claims |
| Boehringer IngelheimSpiriva Respimat | $17 | $6,13612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 967 hematology & oncology providers in New York.
Other hematology & oncology in New York
- Michael SchusterNew York$1.6M
- Charles SawyersNew York$1.6M
- Manuel Hidalgo-MedinaNew York$1.4M
- Ross LevineNew York$968K
- Joshua SabariNew York$761K
- Gail RobozNew York$738K
- Jeffrey LaurenceNew York$640K
- John AllanNew York$580K
- Ilan ShapiraNew York$475K
- John MascarenhasNew York$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.